Primary HPV Screening Intervals Could Be Extended
By Elana Gotkine HealthDay Reporter
FRIDAY, May 24, 2024 -- Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) eight years after negative HPV screening comparable to risk after three years in cytology cohorts, according to a study published online May 22 in Cancer Epidemiology, Biomarkers & Prevention.
Anna Gottschlich, Ph.D., M.P.H., from the BC Women's Hospital and Health Services in Vancouver, British Columbia, Canada, and colleagues conducted a longitudinal cohort study involving women and individuals with a cervix (WIC) who received one to two negative HPV screens (5,546 in the HPV1 cohort; 6,624 in the HPV2 cohort) and WIC with one to two normal cytology results (782,297 in the BCS1 cohort; 673,778 in the BCS2 cohort). Participants were followed for 14 years.
The researchers found that after eight years, the cumulative risks for CIN2+ were 3.2 and 2.7 per 1,000 in HPV1 and HPV2, respectively. This was comparable to the cytology cohort risk after three years (3.3 and 2.5 per 1,000 in BCS1 and BCS2, respectively). After 10 years, the cumulative risk for CIN2+ was low in the HPV cohorts (4.7 and 3.9 per 1,000 in HPV1 and HPV2, respectively).
"These findings should provide assurance that the five-year interval recommended for HPV screening is even safer than the three-year interval for cytology screening," Gottschlich said in a statement.
Two authors disclosed ties to the pharmaceutical industry; one has a patent registered on DNA methylation markers for early detection of cervical cancer.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Past-Year Pap Testing Rates Were Lower in 2022 Than 2019
FRIDAY, June 14, 2024 -- Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study...
At-School Vaccination Boosts HPV Vaccination Coverage
THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...
ASCO: HPV Vaccination Positively Affecting More Than Just Cervical Cancer Risk
THURSDAY, May 23, 2024 -- Human papillomavirus (HPV) vaccination is associated with reduced odds of several types of HPV-related cancers, not just cervical cancer, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.